Role of C-reactive protein in cerebrovascular disease: a critical review

被引:33
作者
Di Napoli, Mario [1 ,2 ]
Elkind, Mitchell S. V. [3 ,4 ]
Agustin Godoy, Daniel [5 ]
Singh, Puneetpal [6 ]
Papa, Francesca [2 ]
Popa-Wagner, Aurel [7 ,8 ]
机构
[1] San Camillo de Lellis Gen Hosp, Neurol Serv, Rieti, Italy
[2] SMDN Ctr Cardiovasc Med & Cerebrovasc Dis Prevent, Neurol Sect, I-67039 Sulmona, AQ, Italy
[3] Columbia Univ, Mailman Sch Publ Hlth, Coll Phys & Surg, Dept Neurol, New York, NY USA
[4] Columbia Univ, Mailman Sch Publ Hlth, Epidemiol, New York, NY USA
[5] Sanatorio Pasteur, Neurocrit Care Unit, Catamarca, Argentina
[6] Punjabi Univ, Dept Human Biol, Mol Genet Lab, Patiala, Punjab, India
[7] Univ Med, Clin Neurol, Greifswald, Germany
[8] Univ Med & Pharm, Craiova, Romania
关键词
cerebral ischemia; cerebrovascular disease; C-reactive protein; inflammation; intracerebral hemorrhage; stroke;
D O I
10.1586/ERC.11.159
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
C-reactive protein (CRP) is a blood marker of inflammation and a hallmark of the acute-phase response. Its elevation bears negative prognostic implications for many conditions and it has also been shown to be a nonspecific predictor of long-term risk of cerebrovascular disease (CVD) in several populations, while elevations of CRP associated with the major acute-phase response following ischemic or hemorrhagic stroke are associated with death and vascular complications. High-sensitivity assays that accurately measure levels of CRP have been proposed for use in risk assessment for CVD and as a prognostic marker after an acute event, although the pathogenic and clinical significance of these associations is controversial. In this article, we critically review the literature in narrative format and describe major epidemiological studies, novel experiments and possible future developments that may inform the debate. In our discussion, we will distinguish the different pathophysiological roles of high circulating CRP concentrations in individuals with acute stroke from the modestly and persistently increased levels of CRP concentration in generally healthy subjects. However, before any clinical application is possible, a critical appraisal of the strengths and deficiencies of the accumulated evidence is required, both to consider the current state of knowledge and to inform the design of future research.
引用
收藏
页码:1565 / 1584
页数:20
相关论文
共 206 条
[1]
Topology and structure of the C1q-binding site on C-reactive protein [J].
Agrawal, A ;
Shrive, AK ;
Greenhough, TJ ;
Volanakis, JE .
JOURNAL OF IMMUNOLOGY, 2001, 166 (06) :3998-4004
[2]
AGRAWAL A, 1994, J IMMUNOL, V152, P5404
[3]
Agrawal A, HEMATOL DISORD DRUG, V10, P235
[4]
Agrawal A, 2009, ADV EXP MED BIOL, V653, P98
[5]
Socioeconomic Position and Inflammatory and Immune Biomarkers of Cardiovascular Disease: Applications to the Panel Study of Income Dynamics [J].
Aiello, Allison E. ;
Kaplan, George A. .
BIODEMOGRAPHY AND SOCIAL BIOLOGY, 2009, 55 (02) :178-205
[6]
Serum C-reactive protein and lipid hydroperoxides in predicting short-term clinical outcome after spontaneous intracerebral hemorrhage [J].
Alexandrova, Margarita L. ;
Danovska, Maya P. .
JOURNAL OF CLINICAL NEUROSCIENCE, 2011, 18 (02) :247-252
[7]
C-Reactive Protein Is a Determinant of First-Ever Stroke: Prospective Nested Case-Referent Study [J].
Andersson, Jonas ;
Johansson, Lars ;
Ladenvall, Per ;
Wiklund, Per-Gunnar ;
Stegmayr, Birgitta ;
Jern, Christina ;
Boman, Kurt .
CEREBROVASCULAR DISEASES, 2009, 27 (06) :544-551
[8]
C-reactive protein predicts further ischemic events in first-ever transient ischemic attack or stroke patients with intracranial large-artery occlusive disease [J].
Arenillas, JF ;
Alvarez-Sabín, J ;
Molina, CA ;
Chacón, P ;
Montaner, J ;
Rovira, A ;
Ibarra, B ;
Quintana, M .
STROKE, 2003, 34 (10) :2463-2468
[9]
Analysis of binding sites in human C-reactive protein for FcγRI, FcγRIIA, and C1q by site-directed mutagenesis [J].
Bang, R ;
Marnell, L ;
Mold, C ;
Stein, MP ;
Du Clos, KT ;
Chivington-Buck, C ;
Du Clos, TW .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (26) :25095-25102
[10]
BARNA BP, 1984, CANCER RES, V44, P305